Newsletter
Sign up for the Fund's newsletter and get the lastest news about the Fund's investments.
Title Sort descending | Period | Programme | |
---|---|---|---|
A holistic digital respiratory therapeutics solution – SiA® (Systematic Intervention Agent) for Asthma, COPD and ILD patients | 2023 - 2024 | Innobooster | |
A holistic digital respiratory therapeutics solution – SiA® (Systematic Intervention Agent) for Asthma, COPD and ILD patients
Period
2023 - 2024
Region
Program
Innobooster Area
Ikke defineret Investment
Percentage
35 Invested
979.125 Budget
2.8 mill. Partners
Briota ApS People
Read more about the project
| |||
A Loudspeaker Parameter Recommender System | 2023 - 2026 | Industrial Researcher | |
A Loudspeaker Parameter Recommender System
Period
2023 - 2026
Region
Program
Erhvervsforsker Area
Ikke defineret Investment
Percentage
40.97 Invested
1.1 mill. Budget
2.6 mill. Formålet med projektet er at udvide det videnskabelige grundlag for maskinlæringsmetoder så de kan bruges i adaptive akustiske systemer. Systemet, der undersøges, er højttalere i et rum og de adaptive faktorer er dels de fysiske forhold i rummet og dels brugerens præferencer for god lydkvalitet som funktion af konteksten. Målet er en markant forøgelse af brugertilfredsheden for et fuldt adaptivt system sammenlignet med et konventionelt system.
Partners
Aalborg University, BANG & OLUFSEN A/S(Fabrik 4) People
Read more about the project
| |||
A medical device to detect epileptic seizures | 2024 - 2025 | Innofounder | |
A medical device to detect epileptic seizures
Period
2024 - 2025
Region
Program
Innofounder Area
Ikke defineret Investment
Percentage
100 Invested
760.000 Budget
760.000 Long-Term Electroencephalographic Monitoring (LTVEM) is used for more precise diagnostic information to optimize treatment and care for epileptic patients. LTVEM mainly takes place in hospitals and patients can be referred for LTVEM for 24 hours or up to several days. LTVEM produces a vast amount of EEG data that must be reviewed and validated – largely a manual procedure today that can take 6-8 hours for each patient, using time of technicians and neurologists. We are developing cNode, a device that integrates with existing LTVEM equipment to avoid the need for manual analysis of the EEG data. The firsts step in the cNode process converts the EEG signal into spikes, similar to the way of communication of the brain. The spike data is fed into a Spike Neural Network (SNN) with on-chip learning and a unique pattern recognition ability. The output is the seizure onset and timestamp. The cNode prototype is integrated on an electronic board and its functionality and ability to detect seizure has been confirmed in various in-vitro and human in-silico models
Partners
CENEXUM Technologies ApS People
Read more about the project
| |||
A medical device to prevent ureter injuries | 2024 - 2025 | Innobooster | |
A medical device to prevent ureter injuries
Period
2024 - 2025
Region
Program
Innobooster Area
Ikke defineret Investment
Percentage
35 Invested
625.800 Budget
1.8 mill. Partners
Rheia Medical Aps People
Read more about the project
| |||
A modular approach for establishing clinical tracheostomies | 2023 - 2024 | Innobooster | |
A modular approach for establishing clinical tracheostomies
Period
2023 - 2024
Region
Program
Innobooster Area
Ikke defineret Investment
Percentage
35 Invested
1.1 mill. Budget
3.1 mill. Partners
Innotrach People
Read more about the project
| |||
A Modular Microbial Biostimulant for Sustainable Agriculture | 2022 - 2023 | Innobooster | |
A Modular Microbial Biostimulant for Sustainable Agriculture
Period
2022 - 2023
Region
Region Syddanmark Program
Innobooster Area
Ikke defineret Investment
Percentage
35 Invested
1.4 mill. Budget
4.1 mill. Partners
Bioomix APS People
Bioomix ApS
Read more about the project
| |||
A molecular display platform for screening and direct selection of functionally active peptides | 2019 - 2021 | Industrial Researcher | |
A molecular display platform for screening and direct selection of functionally active peptides
Period
2019 - 2021
Region
Region Hovedstaden Program
Erhvervsforsker Area
Biotek, Medico og Sundhed Investment
Percentage
45.61 Invested
828.000 Budget
1.8 mill. Partners
Danmarks Tekniske Universitet, ZEALAND PHARMA A/S People
ZEALAND PHARMA A/S
Read more about the project
| |||
A more sustainable global agriculture powered by carbon credits | 2023 - 2023 | Innobooster | |
A more sustainable global agriculture powered by carbon credits
Period
2023 - 2023
Region
Program
Innobooster Area
Ikke defineret Investment
Percentage
35 Invested
836.500 Budget
2.4 mill. Partners
ruumi ApS People
Read more about the project
| |||
A new AI-accelerated model for sustainable stormwater management | 2023 - 2024 | Innobooster | |
A new AI-accelerated model for sustainable stormwater management
Period
2023 - 2024
Region
Program
Innobooster Area
Ikke defineret Investment
Percentage
35 Invested
903.000 Budget
2.6 mill. Partners
WaterZerv ApS People
Read more about the project
| |||
A new antifungal agent – a possible game changer in fungal treatment | 2024 - 2024 | Innoexplorer | |
A new antifungal agent – a possible game changer in fungal treatment
Period
2024 - 2024
Region
Program
Innoexplorer Area
Ikke defineret Investment
Percentage
100 Invested
1.5 mill. Budget
1.5 mill. Partners
Rigshospitalet People
Read more about the project
| |||
A New Approach for Stability and Immunogenicity Assessment of Biopharmaceuticals | 2019 - 2022 | Industrial Researcher | |
A New Approach for Stability and Immunogenicity Assessment of Biopharmaceuticals
Period
2019 - 2022
Region
Region Hovedstaden Program
Erhvervsforsker Area
Biotek, Medico og Sundhed Investment
Percentage
47.06 Invested
1.1 mill. Budget
2.3 mill. Partners
University of Copenhagen, Fida Biosystems ApS People
Fida Biosystems ApS
Read more about the project
| |||
A new approach to understand how lifestyle influences the activity among people with Multiple sclerosis using a person centered design | 2016 - 2019 | Industrial Researcher | |
A new approach to understand how lifestyle influences the activity among people with Multiple sclerosis using a person centered design
Period
2016 - 2019
Region
Region Hovedstaden Program
Erhvervsforsker Area
Ikke defineret Investment
Percentage
40.89 Invested
948.746 Budget
2.3 mill. Partners
University of Copenhagen, SCLEROSEFORENINGEN People
SCLEROSEFORENINGEN
Read more about the project
| |||
A new cost-neutral injection pen as an alternative to syringes for the 12 million resource poor people buying insulin in vials though minimum feature innovation | 2019 - 2020 | Innofounder | |
A new cost-neutral injection pen as an alternative to syringes for the 12 million resource poor people buying insulin in vials though minimum feature innovation
Period
2019 - 2020
Region
Region Hovedstaden Program
Innofounder Area
Biotek, Medico og Sundhed Investment
Percentage
100 Invested
460.000 Budget
460.000 Partners
GO-PEN ApS People
GO-PEN ApS
Read more about the project
| |||
A new diagnostic tool for neuropathic diseases | 2023 - 2024 | Innofounder | |
A new diagnostic tool for neuropathic diseases
Period
2023 - 2024
Region
Program
Innofounder Area
Ikke defineret Investment
Percentage
100 Invested
430.000 Budget
430.000 Til afgørende forskel for dialyse-, diabetes- og cancerpatienter vil vi udbrede anvendelse af neurologiske målinger og muliggøre tidligere diagnosticering, forbedret behandling og medicinering. I dag henvises et få patienter med mulig for neurologiske følgesygdom til elektrofysiologiske undersøgelser for at afdække tidlig nervedysfunktioner. Dette skyldes at undersøgelser foregår ved et omfattende og dyrt setup, på særlige neurofysiologiske klinikker.
Ved tidlig diagnostik, kan følgesmerte under andet sygdom mindskes. Med Wenemea ser vi derfor et paradigmeskift i behandlingen af sensoriske og motoriske degenerative nervesygdomme i det perifere nervesystem.
Vi præsenterer et helt nyt device til nervemålinger - Wenemea - som er et kompakt, letvægts, neurosensor device til et tilgængeligt prisniveau. Således repræsenterer vi et paradigmeskifte indenfor nerveundersøgelse. Konkret vil vi udfylde hullet mellem let tilgængelig og transportabel elektrofysiologisk hardware og avanceret software til at bestemme nervesygdomme. Det er vores ambition at udvikle en lille, trådløs, batteridrevet og billig enhed i modsætning til det nuværende.
Samtidigt udvikler og eksekver vi en Go2Market-strategi, som definerer vores ”value proposition” og markedstilgang. Vi har udviklet en basis-prototype, som vi ønsker at videreudvikle understøttende en samlet forretningsplan, som detaljeret og struktureret beskriver det forestående udviklings-, test-, design/koncept- og kommercialiseringsarbejde
Partners
Wenemea ApS People
Read more about the project
| |||
A new generation of Pattern Scanning Photocoagulator systems for multi-spot laser treatment of ophthalmic diseases | 2021 - 2023 | Innobooster | |
A new generation of Pattern Scanning Photocoagulator systems for multi-spot laser treatment of ophthalmic diseases
Period
2021 - 2023
Region
Region Hovedstaden Program
Innobooster Area
Ikke defineret Investment
Percentage
33 Invested
4.4 mill. Budget
13.2 mill. Partners
Norlase Aps People
NORLASE ApS
Read more about the project
|